Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_assertion type Assertion NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_head.
- NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_assertion description "[The ages at the time of 50% thrombosis-free survival were as follows: 34 years for AT deficiency, (19 years with FVL, 21 years with PT20210A), 62 years for PC deficiency (33 years with FVL, 44 years with PT20210A), 37 years for PS deficiency (24 years with FVL, 36 years with PT20210A), 50 years for the FVL mutation (52 years with PT20210A), and 65 years for the PT20210A mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_provenance.
- NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_assertion evidence source_evidence_literature NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_provenance.
- NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_assertion SIO_000772 11694407 NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_provenance.
- NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_assertion wasDerivedFrom befree-20140225 NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_provenance.
- NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_assertion wasGeneratedBy ECO_0000203 NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_provenance.